Yves Chalandon,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Xavier Thomas,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Sandrine Hayette,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Jean-Michel Cayuela,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Claire Abbal,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Françoise Huguet,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Emmanuel Raffoux,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Thibaut Leguay,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Philippe Rousselot,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Stéphane Lepretre,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Martine Escoffre-Barbe,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Sébastien Maury,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Céline Berthon,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Emmanuelle Tavernier,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Jean-François Lambert,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Marina Lafage-Pochitaloff,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Véronique Lhéritier,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Sylvie Chevret,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Norbert Ifrah,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL),Hervé Dombret,for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)

View Articletitled, Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

Supplemental data

IMMUNOBIOLOGY

Altered lymphopoiesis and immunodeficiency in miR-142 null mice

Nicholas J. Kramer,Wei-Le Wang,Estefany Y. Reyes,Bijender Kumar,Ching-Cheng Chen,Chandran Ramakrishna,Edouard M. Cantin,Steven L. Vonderfecht,Konstantin D. Taganov,Nelson Chau,Mark P. Boldin

View Articletitled, Altered lymphopoiesis and immunodeficiency in miR-142 null mice

Supplemental data

LYMPHOID NEOPLASIA

Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation

Taeko Wada,Daisuke Koyama,Jiro Kikuchi,Hiroaki Honda,Yusuke Furukawa

View Articletitled, Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation

Supplemental data

Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A

Francesca Zonta,Mario Angelo Pagano,Livio Trentin,Elena Tibaldi,Federica Frezzato,Valentina Trimarco,Monica Facco,Giuseppe Zagotto,Valeria Pavan,Giovanni Ribaudo,Luciana Bordin,Gianpietro Semenzato,Anna Maria Brunati

View Articletitled, Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A

Supplemental data

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
Brief Report

Jeffrey R. Sawyer,Erming Tian,Christoph J. Heuck,Donald J. Johann,Joshua Epstein,Charles M. Swanson,Janet L. Lukacs,Regina Lichti Binz,Marian Johnson,Gael Sammartino,Maurizio Zangari,Faith E. Davies,Frits van Rhee,Gareth J. Morgan,Bart Barlogie

View Articletitled, Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma

Supplemental data

MYELOID NEOPLASIA

RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug

Martin Wermke,Aylin Camgoz,Maciej Paszkowski-Rogacz,Sebastian Thieme,Malte von Bonin,Andreas Dahl,Uwe Platzbecker,Mirko Theis,Gerhard Ehninger,Sebastian Brenner,Martin Bornhäuser,Frank Buchholz

View Articletitled, RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug

Supplemental data

PLATELETS AND THROMBOPOIESIS

Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development

Kate L. Lowe,Brenda A. Finney,Carsten Deppermann,René Hägerling,Salomé L. Gazit,Jon Frampton,Christopher Buckley,Eric Camerer,Bernhard Nieswandt,Friedemann Kiefer,Steve P. Watson

View Articletitled, Podoplanin and CLEC-2 drive cerebrovascular patterning and integrity during development

Supplemental data

TRANSPLANTATION

Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells

Nancy Y. Villa,Clive H. Wasserfall,Amy M. Meacham,Elizabeth Wise,Winnie Chan,John R. Wingard,Grant McFadden,Christopher R. Cogle

View Articletitled, Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells

Supplemental data

Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies
Clinical Trials & Observations

Sachiko Seo,Christian Renaud,Jane M. Kuypers,Charles Y. Chiu,Meei-Li Huang,Erik Samayoa,Hu Xie,Guixia Yu,Cynthia E. Fisher,Ted A. Gooley,Steven Miller,Robert C. Hackman,David Myerson,Ruth H. Sedlak,Yae-Jean Kim,Takahiro Fukuda,David N. Fredricks,David K. Madtes,Keith R. Jerome,Michael Boeckh

View Articletitled, Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies

Supplemental data

Alternative donor hematopoietic cell transplantation for Fanconi anemia

Margaret L. MacMillan,Todd E. DeFor,Jo-Anne H. Young,Kathryn E. Dusenbery,Bruce R. Blazar,Arne Slungaard,Heather Zierhut,Daniel J. Weisdorf,John E. Wagner

View Articletitled, Alternative donor hematopoietic cell transplantation for Fanconi anemia

VASCULAR BIOLOGY

Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease

Stéphane M. Camus,João A. De Moraes,Philippe Bonnin,Paul Abbyad,Sylvain Le Jeune,François Lionnet,Laurent Loufrani,Linda Grimaud,Jean-Christophe Lambry,Dominique Charue,Laurent Kiger,Jean-Marie Renard,Claire Larroque,Hervé Le Clésiau,Alain Tedgui,Patrick Bruneval,Christina Barja-Fidalgo,Antigoni Alexandrou,Pierre-Louis Tharaux,Chantal M. Boulanger,Olivier P. Blanc-Brude

View Articletitled, Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease

Supplemental data

BLOOD WORK

Misleading acute promyelocytic leukemia morphology

Soraya Wuillème,Yannick Le Bris

View Articletitled, Misleading acute promyelocytic leukemia morphology

CORRESPONDENCE

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A
Clinical Trials & Observations

Erik Berntorp,Alfonso Iorio

View Articletitled, Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product
Clinical Trials & Observations

Thierry Calvez,Hervé Chambost,Patrick Lutz,Chantal Rothschild,Jenny Goudemand

View Articletitled, Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product

Supplemental data

Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies
Clinical Trials & Observations

Matteo Nicola Dario Di Minno,Emanuela Marchesini,Lelia Valdrè

View Articletitled, Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies

Lactate dehydrogenase isoenzyme 3 and hemolysis in sickle cell anemia: a possible correlation?

Grazielle Mecabo,Mihoko Yamamoto,Thais Priscila Biassi,Maria Stella Figueiredo

View Articletitled, Lactate dehydrogenase isoenzyme 3 and hemolysis in sickle cell anemia: a possible correlation?

ERRATA

Rivetti di Val Cervo P, Tucci P, Majid A, et al. p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood. 2009;113(25):6498-6499.

View Articletitled, Rivetti di Val Cervo P, Tucci P, Majid A, et al. p73, miR106b, miR34a, and Itch in chronic lymphocytic leukemia. Blood. 2009;113(25):6498-6499.

Yao H, Duan M, Buch S. Cocaine-mediated induction of platelet-derived growth factor: implication for increased vascular permeability. Blood. 2011;117(8):2538-2547.

View Articletitled, Yao H, Duan M, Buch S. Cocaine-mediated induction of platelet-derived growth factor: implication for increased vascular permeability. Blood. 2011;117(8):2538-2547.

Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopenia. Blood. 2011;117(13):3658-3668.

View Articletitled, Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopenia. Blood. 2011;117(13):3658-3668.

Cover Image

Cover Image

Masson trichrome staining of kidneys from mice with sickle cell disease treated with heme-laden microparticles. Erythrocytes are marked in dark red. There is vascular congestion in capillaries running in the corticomedullar region. See the article by Camus et al on page 3805.
Front Matter
Table of Contents
Back Matter
Advertising
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Licking the wound with procoagulant vesicles

Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study

CAR T-cells in autoimmunity: game changer or stepping stone?

Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH

How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Issue Archive

Table of Contents

INSIDE BLOOD COMMENTARIES

Time to tune the treatment of Ph+ ALL Clinical Trials & Observations

PLENARY PAPER

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing Clinical Trials & Observations

BLOOD SPOTLIGHT

REVIEW ARTICLE

HOW I TREAT

How I treat acute lymphoblastic leukemia in older adolescents and young adults Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia Clinical Trials & Observations

IMMUNOBIOLOGY

LYMPHOID NEOPLASIA

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma Brief Report

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

TRANSPLANTATION

Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies Clinical Trials & Observations

VASCULAR BIOLOGY

BLOOD WORK

CORRESPONDENCE

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A Clinical Trials & Observations

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product Clinical Trials & Observations

Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies Clinical Trials & Observations

ERRATA

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Time to tune the treatment of Ph+ ALL
Clinical Trials & Observations

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
Clinical Trials & Observations

How I treat acute lymphoblastic leukemia in older adolescents and young adults
Clinical Trials & Observations

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Clinical Trials & Observations

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
Brief Report

Idiopathic pneumonia syndrome after hematopoietic cell transplantation: evidence of occult infectious etiologies
Clinical Trials & Observations

Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A
Clinical Trials & Observations

Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product
Clinical Trials & Observations

Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies
Clinical Trials & Observations